SCHEMBL25366200

SCHEMBL25366200

CC(C)(C)CCC(NC(=O)N1CCCOCC1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CTSS P25774 13/20 0.46
HTT P42858 1/20 0.43
CAPN1 P07384 1/20 0.42
GRN P28799 1/20 0.40
SORT1 Q99523 1/20 0.40
CTSL P07711 1/20 0.39
CTSK P43235 1/20 0.39
PIN1 Q13526 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366197 1.00 PKM (0.49) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL25364988 0.95 PKM (0.50) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL25364983 0.95 PKM (0.50) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL4828729 0.83 CTSS (0.60) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL4828718 0.83 CTSS (0.60) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL3873469 0.82 PKM (0.49) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL6803162 0.81 CTSS (0.54) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL6801412 0.79 HTT (0.56) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL3870379 0.78 CTSS (0.46) PKMSMN1; SMN2CTSSHTTCAPN1
SCHEMBL3870801 0.78 CTSS (0.46) PKMSMN1; SMN2CTSSHTTCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161321-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES VESPER BIO APS (DK) 2025-05-22 US claimed
EP-4486443-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES Vesper Bio Aps (DK) 2025-01-08 EP claimed
WO-2023161505-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES INSUSENSE ApS (DK) 2023-08-31 WO claimed
EP-4234014-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES Insusense ApS (DK) 2023-08-30 EP claimed
US-20250161321-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES VESPER BIO APS (DK) 2025-05-22 US disclosed
EP-4486443-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES Vesper Bio Aps (DK) 2025-01-08 EP disclosed
WO-2023161505-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES INSUSENSE ApS (DK) 2023-08-31 WO disclosed
EP-4234014-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES Insusense ApS (DK) 2023-08-30 EP disclosed
EP-4234014-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES Insusense ApS (DK) 2023-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161321-A1 AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES SORT1, SLC14A1, CTSA PKM 4036/4885SMN1; SMN2 788/4885CTSS 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.